HK1201541A1 - Tumour necrosis factor receptor fusion proteins and methods of using the same - Google Patents

Tumour necrosis factor receptor fusion proteins and methods of using the same Download PDF

Info

Publication number
HK1201541A1
HK1201541A1 HK15102126.6A HK15102126A HK1201541A1 HK 1201541 A1 HK1201541 A1 HK 1201541A1 HK 15102126 A HK15102126 A HK 15102126A HK 1201541 A1 HK1201541 A1 HK 1201541A1
Authority
HK
Hong Kong
Prior art keywords
methods
same
fusion proteins
necrosis factor
factor receptor
Prior art date
Application number
HK15102126.6A
Other languages
English (en)
Chinese (zh)
Inventor
Alexander Drew
David Gearing
Original Assignee
Nexvet Australia Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nexvet Australia Pty Ltd filed Critical Nexvet Australia Pty Ltd
Publication of HK1201541A1 publication Critical patent/HK1201541A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
HK15102126.6A 2012-02-22 2013-02-22 Tumour necrosis factor receptor fusion proteins and methods of using the same HK1201541A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261601712P 2012-02-22 2012-02-22
US201261601712P 2012-02-22
PCT/GB2013/050433 WO2013124666A1 (en) 2012-02-22 2013-02-22 Tumour necrosis factor receptor fusion proteins and methods of using the same

Publications (1)

Publication Number Publication Date
HK1201541A1 true HK1201541A1 (en) 2015-09-04

Family

ID=47754861

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15102126.6A HK1201541A1 (en) 2012-02-22 2013-02-22 Tumour necrosis factor receptor fusion proteins and methods of using the same

Country Status (11)

Country Link
US (2) US9731007B2 (https=)
EP (1) EP2817326A1 (https=)
JP (1) JP2015509714A (https=)
KR (1) KR20140135766A (https=)
CN (1) CN104159916A (https=)
AU (1) AU2013223801B2 (https=)
CA (1) CA2865288A1 (https=)
HK (1) HK1201541A1 (https=)
NZ (1) NZ629309A (https=)
SG (1) SG11201405013RA (https=)
WO (1) WO2013124666A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6701079B2 (ja) * 2013-12-20 2020-05-27 インターベット インターナショナル ベー． フェー． ヒトｐｄ−１に対するイヌ化マウス抗体
JP2018504911A (ja) * 2015-01-29 2018-02-22 ネックスヴェット オーストラリア プロプライエタリー リミテッド 治療及び診断剤
KR20170138426A (ko) * 2015-03-13 2017-12-15 삼성바이오에피스 주식회사 항-tnf-알파 폴리펩티드 조성물 및 그 용도
CN104840945B (zh) * 2015-03-25 2018-09-07 上海市松江区中心医院 诱骗受体3在治疗脓毒症药物中的应用
US11091556B2 (en) 2015-12-18 2021-08-17 Intervet Inc. Caninized human antibodies to human IL-4R alpha
WO2017102920A1 (en) 2015-12-18 2017-06-22 Intervet International B.V. Caninized human antibodies to human and canine il-4r alpha
WO2017123642A1 (en) * 2016-01-12 2017-07-20 The Trustees Of The University Of Pennsylvania Methods and uses of osteoclast associated receptor (oscar) for prevention and treatment of osteoarthritis
BR112020002871A2 (pt) * 2017-08-15 2020-07-28 Kindred Biosciences, Inc. variantes fc de igg para uso veterinário
JP2020080784A (ja) * 2018-11-29 2020-06-04 シスメックス株式会社 融合ポリペプチド、融合ポリペプチドの製造方法、及び融合ポリペプチドをコードするｄｎａ

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU640397B2 (en) 1989-08-25 1993-08-26 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Dog-mouse heterohybridoma and gene fragment coding for constant region of canine immunoglobulin
TWI364458B (en) * 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
AU2006230419A1 (en) * 2005-03-31 2006-10-05 Targeted Genetics Corporation Methods for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders
EP2725037A1 (en) * 2008-09-04 2014-04-30 Vet Therapeutics, Inc. Monoclonal antibodies binding canine CD20
CN101747440B (zh) * 2008-12-18 2014-05-07 嘉和生物药业有限公司 一种TNFR-Fc融合蛋白及其用途
CN101760506A (zh) * 2008-12-25 2010-06-30 欣润(上海)生物药业有限公司 一种rhTNFR-Fc融合蛋白生物学活性的检测方法
US8181211B2 (en) 2009-03-30 2012-05-15 John Mezzalingua Associates, Inc. Total bandwidth conditioning device
WO2010117448A2 (en) * 2009-04-05 2010-10-14 Provenance Biopharmaceuticals Corp. Chimeric immunocytokines and methods of use thereof
EP2435477A1 (en) * 2009-05-28 2012-04-04 Glaxo Group Limited Antigen-binding proteins

Also Published As

Publication number Publication date
CA2865288A1 (en) 2013-08-29
JP2015509714A (ja) 2015-04-02
KR20140135766A (ko) 2014-11-26
US20150037333A1 (en) 2015-02-05
AU2013223801A1 (en) 2014-08-28
EP2817326A1 (en) 2014-12-31
CN104159916A (zh) 2014-11-19
NZ629309A (en) 2016-03-31
SG11201405013RA (en) 2014-09-26
US20180153987A1 (en) 2018-06-07
AU2013223801B2 (en) 2016-02-25
US9731007B2 (en) 2017-08-15
WO2013124666A1 (en) 2013-08-29

Similar Documents

Publication Publication Date Title
HK1201541A1 (en) Tumour necrosis factor receptor fusion proteins and methods of using the same
IL287835A (en) Chimeric antigenic receptors against fc 5-like receptor and their use
IL293220A (en) Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
MX2023008559A (es) Proteínas de fusión fc heterodiméricas il15/il15ra.
EP3733716A4 (en) DIMERAL FUSION PROTEIN USING ANTIBODY FC REGION AS A SKELETON AND ASSOCIATED USE
MX421100B (es) Composiciones del polipeptido de fusion tnfr: fc exentas de arginina y metodos de uso
PH12017501039A1 (en) Antibodies targeting g-protein coupled receptor and methods of use
HK1220214A1 (zh) Fc变体
MX2020011064A (es) Inmunoglobulinas heterodimericas.
MX2016010953A (es) Proteinas de fc multimericas.
PH12018501177B1 (en) Antibodies targeting fc receptor-like 5 and methods of use
GB2549632B (en) Fusion protein comprising three binding domains to 5T4 and CD3
HK1249405A1 (zh) 抗dll3嵌合抗原受体及其使用方法
PH12013502378A1 (en) Fc RECEPTOR BINDING PROTEINS
EP2970490A4 (en) Antibodies to mica and micb proteins
MX2016006301A (es) Construcciones de unión a antígeno monovalente que se dirigen a egfr y/o her2, y sus usos.
WO2010083253A3 (en) Cd47 related compositions and methods for treating immunological diseases and disorders
EP3094653A4 (en) Chimeric antigen receptors (cars) having mutations in the fc spacer region and methods for their use
IL245754B (en) Liquid formulation of fusion protein containing tnfr and fc region
NZ611428A (en) Novel modulators and methods of use
PL2919801T3 (pl) Stabilna kompozycja farmaceutyczna białka fuzyjnego TNFR:FC etanerceptu
EP3000825A4 (en) Trans-tumoral peptide specific to neuropilin and fusion protein having same peptide fused therein
EP3068604A4 (en) Energy director joint design for ultrasonic welding of thermoplastics
EP3131917A4 (en) Humanized and chimeric monoclonal antibodies to cd99
HK40039976A (en) Natural killer cells engineered to express chimeric antigen receptors with immune checkpoint blockade